Twinrix® vaccination schedules among injecting drug users

Expert Opinion on Biological Therapy

Volumn 7, Issue 3, 2007, Pages 379-389

  Brim, Nancy ^a   Zaller, Nickolas ^a,b   Taylor, Lynn E ^a,b   Feller, Ed ^a  

^a BROWN UNIVERSITY   (United States)

^b MIRIAM HOSPITAL   (United States)

Author keywords

Hepatitis; IDU; Twinrix; Vaccine

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; VACCINE;

DRUG USE; HEPATITIS A; HEPATITIS B; HUMAN; PREVALENCE; REVIEW; SEROCONVERSION; UNITED STATES; VACCINATION; VIRUS IMMUNITY; ARTICLE; DRUG ADMINISTRATION; SUBSTANCE ABUSE;

HEPATITIS A VIRUS; HEPATITIS B VIRUS;

DRUG ADMINISTRATION SCHEDULE; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS; VACCINES, COMBINED;

EID: 33847762162     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.3.379     Document Type: Review

References (77)

1. GLAXOSMITHKLINE BIOLOGICALS: Twinrix Prescribing Information, Issue 4. Rixensart, Belgium (2003).
2. GLAXOSMITHKLINE BIOLOGICALS: Twinrix and Twinrix Junior Consumer Medicine Information, Issue 4. Rixensart, Belgium (2003).
3. HERSHEY JH, SCHOWALTER L, BAILEY SB: Public health perspective on vaccine-preventable hepatitis: integrating hepatitis A and B vaccines into public health settings. Am. J. Med. (2005) 118(10A):100S-108S.
4. CAREY J, PERLMAN DC, FRIEDMANN P, KAPLAN WM et al.: Knowledge of hepatitis among active drug injectors at a syringe exchange program. J. Subst. Abuse Treat. (2005) 29(1):47-53.
5. PERRETT K, GRANEROD J, CROWCROFT N, CARLISLE R: Changing epidemiology of hepatitis A: should we be doing more to vaccinate injecting drug users? Commun. Dis. Public Health (2003) 6(2):97-100.
6. CHLABICZ S: Risks associated with hepatitis infection in patients with hepatitis C and opportunities for prophylaxis. Przegl. Epidemiol. (2003) 57(3):465-470.
7. VILLANO SA, NELSON KE, VLAHOV D, PURCELL RH, SAAH AJ, THOMAS DL: Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. Clin. Infect. Dis. (1997) 25:726-728.
8. BELL BP, KRUSZON-MORAN D, SHAPIRO CN, LAMBERT SB, MCQUILLLAN GM, MARGOLIS HS: Hepatitis A virus infection in the United States: serologic results from the Third National Health and Nutrition Examination Survey. Vaccine (2005) 23(50):5798-5806.
9. KOFF RS: Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. J. Clin. Gastroenterol. (2001) 33(1):20-26.
10. CENTERS FOR DISEASE CONTROL AND PREVENTION: Hepatitis A among drug users. MMWR Morb. Mortal. Wkly Rep. (1988) 37:297-300.
11. ALTICE FL, BRUCE RD, WALTON MR, BUITRAGO MI: Adherence to hepatitis B virus vaccination at syringe exchange sites. J. Urban Health (2005) 82(1):151-161.
12. OMPAD DC, GALEA S, WU Y: Acceptance and completion of hepatitis B vaccination among drug users in New York city. Commun. Dis. Public Health (2004) 27(4):294-300.
13. KUO I, SHERMAN SG, THOMAS DL, STRATHDEE SA: Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Defend. (2004) 73(1):69-78.
14. CARTER H, ROBINSON G, HANLON C, HAILWOOD C, MASSAROTTO A: Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. NZ Med. J. (2001) 114(1136):324-326.
15. GARFEIN RS, VLAHOV D, GALAI N, DOHERTY MC, NELSON KE: Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am. J. Public Health (1996) 86:655-661.
16. LEVINE OS, VLAHOV D, KOEHLER J, COHN S, SPRONK AM, NELSON KE:. Seroepidemiology of hepatitis B virus in a population of injecting drug users. Association with drug injection patterns. Am. J. Epidemiol. (1995): 142(3):331-341.
17. GILBERT RL, COSTELLA A, PIPER M, GILL ON: Increasing hepatitis B vaccination coverage in prisons in England and Wales. Commun. Dis. Public Health (2004); 7:306-311.
18. GOLDSTEIN ST, ALTER MJ, WILLIAMS IT et al.: Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implication for vaccine programs. J. Infect. Dis. (2002) 185:713-719.
19. MAST EE, WILLIAMS IT, ALTER MJ, MARGOLIS HS: Hepatitis B vaccination of adolescents and high-risk groups in the United States. Vaccine (1998) 16(Suppl. 1):S27-S29.
20. MAST EE, MAHONY FJ, ALTER MJ: Progress toward elimination of hepatitis B virus transmission in the United States. Vaccine (1998) 16(Suppl. 1):S48-S51.
21. RICH JD, CHING CG, LALLY MA et al.: A review of the case for hepatitis B vaccination of high-risk adults. Am. J. Med. (2003) 114:316-318.
22. AMBROSCH F, WIEDERMANN G, ANDRE FE et al.: Clinical and immunological investigation of a new combined hepatitis A and B vaccine. J. Med. Virol. (1994) 44:452-456.
23. REUTTER J, BART PA, FRANCIOLI P, SAFARY A, FREI PC: Production of antibody to hepatitis A virus and hepatitis B surface antigen measured after combined hepatitis A/hepatitis B vaccination in 242 adult volunteers. J. Viral Hep. (1998) 5(3):205-211.
24. NOTHDURFT HD, DIETRICH M, ZUCKERMAN JN et al.: A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine (2002) 20(7-8):1157-1162.
25. HEPTONSTALL J: Strategies to ensure delivery of hepatitis B vaccine to injecting drug users. Commun. Dis. Public Health (1999) 2(3):174-177.
26. DES JARLAIS DC, FISHER DG, NEWMAN JC et al.: Providing hepatitis B vaccination to injection drug users: referral to health clinics versus on-site vaccination at a syringe exchange program. Am. J. Public Health (2001) 91:1791-1792.
27. SEAL KH, OCHOA KC, HAHN JA, TULSKY JP, EDLIN BR, MOSS AR: Risk of hepatitis infection among young injection drug users in San Francisco: opportunities for intervention. West J. Med. (2000) 172(1):16-20.
28. SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION OFFICE OF APPLIED STUDIES: Treatment Episode Data Set (TEDS): 2003. Discharges from Substance Abuse Treatment Centers. DASIS SERIES S-30, DHHS Publication No. (SMA) 06-4139. Rockville, MD, USA (2006).
29. ROGERS N, LUBMAN DI: An accelerated hepatitis B vaccination schedule for young drug users. Aust. NZ Public Health (2005) 29(4):305-307.
30. CHRISTENSEN PB, FISKER N, KRARUP HB et al.: Hepatitis B vaccination in prison with a 3 week schedule is more efficient than the standard 6 month schedule. Vaccine (2004) 22(29-30):3897-3901.
31. LUGOBONI F, QUAGLIO G, PAJUSCO B et al.: Immunogenicity, reactogenicity and adherence to a combined hepatitis A and B vaccine in illicit drug users. Addiction (2004) 99(12):1560-1564.
32. LUGOBONI F, MIGLIOZZI S, SCHIESARI F et al.: Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users. Vaccine (1997) 15(9):1014-1016.
33. QUAGLIO G, TALAMINI G, LUGOBONI F et al.: Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. Addiction (2002) 97(8):985-992.
34. LUM PJ, OCHOA KC, HAHN JA et al.: Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study. Am. J. Public Health (2003) 93(6):919-924.
35. CENTERS FOR DISEASE CONTROL AND PREVENTION: Hepatitis B vaccination for injection drug users-Pierce County, Washington 2000. MMWR Morb. Mortal. Wkly Rep. (2001) 50(19):388-392.
36. VAN STEENBERGEN JE: Results of an enhanced-outreach programme of hepatitis B vaccination in the Netherlands (1998-2000) among men who have sex with men, hard drug users, sex workers and heterosexual persons with multiple partners. Working Group Vaccination High-Risk Groups Hepatitis B For The Netherlands. J. Hepatol. (2002) 37(4):507-513.
37. JONES O, SANKAR KN: Audit of outcome of super-accelerated hepatitis B vaccination schedule in a genitourinary medicine clinic. Int. J. STD AIDS (2005) 16(9):636-637.
38. ASBOE D, RICE P, DE RUITER A, BINGHAM JS: Hepatitis B vaccination schedules in genitourinary medicine clinics. Genitourin. Med. (1996) 72(3):210-212.
39. MCMILLAN A: Hepatitis B vaccination of men who have sex with men: experience with an accelerated course of vaccination in a genitourinary medicine clinic. Int. J. STD AIDS (2005) 16(9):633-635.
40. SALTOGLU N, INAL AS, TASOVA Y, KANDEMIR O: Comparison of the accelerated and classic vaccination schedules against hepatitis B: three-week hepatitis B vaccination schedule provides immediate and protective immunity. Ann. Clin. Microbiol. Antimicrob. (2003) 2:10.
41. HARRIES AD, CLARK M, BEECHING NJ, LAVELLE J, MUTTON KJ: Early anti-HBs antibody response to accelerated and to conventional hepatitis B vaccination regimens in healthy persons. J. Infect. (1991) 23(3):251-254.
42. MORRIS DJ, O'NEIL EM, MCCLOY EC, HUI E, GATLEY MS: Hepatitis B surface antibody responses following accelerated vaccination. J. Infect. (1993) 23(4):317-319.
43. BOSNAK M, DIKICI B, BOSNAK V, HASPOLAT K: Accelerated hepatitis B vaccination schedule in childhood. Pediatr. Int. (2002) 44(6):663-665.
44. BELLONI C, PISTORIO A, TINELLI C et al.: Early immunisation with hepatitis B vaccine: a five year study. Vaccine (2000) 18(14):1307-1311.
45. MARCHOU B, EXCLER JL, BOURDERIOUX C et al.: A 3 week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated versus classic vaccination programs. J. Infect. Dis. (2005) 172(1):258-260.
46. MARCOU B, PICOT N, CHAVANET P et al.: Three-week hepatitis B vaccination provides protective immunity. Vaccine (1993) 11(14):1383-1385.
47. NOTHDURFT HD, DIETRICH M, ZUCKERMAN JN, KNOBLOCH J, KERN P, SANGER R: Rapid protection against hepatitis A and B using an accelerated vaccination schedule. Comparison of combined vaccine, Twinrix, with separate vaccines. Biodrugs (2003) 17(Suppl. 1):15-18.
48. MURDOCH DL, GOA K, FIGGITT DP: Combined hepatitis A and B vaccines. A review of their immunogenicity and tolerability. Drugs (2003) 63(23):2625-2649.
49. MINNITI F, BALDO V, TRIVELLO R et al.: Response to HBV vaccine in relation to anti-HCVand anti-HBc positivity: a study in intravenous drug addicts. Vaccine (1999) 17(23-24):3083-3085.
50. RUMI M, COLOMBO M, ROMEO R et al.: Suboptimal response to hepatitis B vaccine in drug users. Arch. Intern. Med. (1991) 151(3):574-578.
51. QUAGLIO G, LUGOBONI F, MEZZELANI PF, DES JARLAIS DC, LECHI A: Hepatitis vaccination among drug users. Vaccine (2006) 24(15):2702-2709.
52. KALLINOWSKI B, JILG W, BUCHHOLZ L, STREMMEL W, ENGLER S: Immunogenicity of an accelerated vaccination regime with a combined hepatitis A/B vaccine in patients with chronic hepatitis C. Z. Gastroenterol. (2003) 41:983-990.
53. WIEDMANN M, LIEBERT UG, OESEN U et al.: Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology (2000) 31(1):230-234.
54. DE MARIA N, IDILMAN R, COLANTONI A, VAN THIEL DH: Increased effective immunogenicity to high dose and short-interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis. J. Viral Hepat. (2001) 8(5):372-376.
55. IDILMAN R, DE MN, COLANTONI A, NADIR A, VAN THIEL DH: The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am. J. Gastroenterol. (2002) 97(28):435-439.
56. MATTOS AA, GOMES EB, TOVO CV, ALEXANDRE CO, REMIAO JO: Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arg. Gastroenterol. (2004) 41(3):180-184.
57. SZMUNESS W, STEVENS CE, HARLEY EJ et al.: Hepatitis B vaccine in medical staff of dialysis units. Efficacy and subtype cross protection. N. Engl. J. Med. (1982) 307(24):1481-1486.
58. WHITTLE HC, INSKIP H, HALL AJ, MENDY M, DOWNES R, HOARE S: Vaccination against hepatitis B and protection against chronic viral carriage in the Gambia. Lancet (1991) 337(8744):747-750.
59. ZUCKERMAN NJ, ZUCKERMAN AJ: Current issues in the immunization against hepatitis A and B. In: Symposium in Immunology VII. Eibl MM, Huber C, Peter HH, Uahn U (Eds), Springer Verlag, Berlin, Germany (1998):15-23.
60. HADLER SC, MARGOLIS HS: Hepatitis B immunization: vaccine types, efficacy and indications for immunization. In: Current Clinical Topics in Infectious Diseases. Remington JS, Swartz MN (Eds), Blackwell Scientific, Boston, MA, USA (1992):282-308.
61. DIENSTAG JL, WERNER BG, POLK et al.: Hepatitis B vaccine in health care personnel: safety, immunogenicity and indicators of efficacy. Ann. Intern. Med. (1984) 101(1):34-40.
62. JILG W, SCHMIDT M, DEINHARDT F: Vaccination against hepatitis B: comparison of three different vaccination schedules. J. Infect. Dis. (1989) 160(5):766-769.
63. LAPLANCHE A, COUROUCE AM, JUNGERS P, BENHAMOU E, CROSNIER J: Hepatitis B vaccination: how long does protection last? Lancet (1984) 2(8400):866.
64. RODRIGO JM, SERRA MA, APARISI L et al.: Immune response to hepatitis B vaccine in parenteral drug abusers. Vaccine (1992) 10(11):798-801.
65. CENTERS FOR DISEASE CONTROL AND PREVENTION: Epidemiology and Prevention of Vaccine-Preventable Diseases (9th edition). Atkinson W, Hamborsky J, McIntyre L, Wolfe S (Eds), Public Health Foundation, Washington DC, USA (2006):218-226.
66. QUAGLIO G, PAJUSCO B, CIVITELLI V et al.: Immunogenicity, reactogenicity and adherence with hepatitis A vaccination among drug users. Drug Alcohol Depend. (2004) 74(1):85-88.
67. CENTERS FOR DISEASE CONTROL AND PREVENTION: 1998 guidelines for the treatment of sexually transmitted diseases. MMWR Recomm. Rep. (1998) 47(RR-1):101-103.
68. ANDRE FE, PATH FRC: Summary of safety and efficacy data on a yeast derived hepatitis B vaccine. Am. J. Med. (1989) 87:14S-20S.
69. BORG L, KHURI E, WELLS A et al.: Methadone-maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination. Addiction (1999) 94(4):489-493.
70. MCGREGOR J, MARKS PJ, HAYWARD A, BELLY, SLACK RC: Factors influencing hepatitis B vaccine uptake in injecting drug users. J. Public Health Med. (2003) 25(2):165-170.
71. CENTERS FOR DISEASE CONTROL AND PREVENTION: Hepatitis B vaccination among high-risk adolescents and adults-San Diego, California, 1998-2001. MMWR Morb. Mortal. Wkly Rep. (2002) 51(28):618-621.
72. CARTER H, ROBINSON G, HANLON C, HAILWOOD C, MASSAROTTO A: Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. NZ Med. J. (2001) 114(1136):324-326.
73. BUDD J, ROBERTSON R, ELTON R: Hepatitis B vaccination and injecting drug users. Br. J. Gen. Pract. (2004) 54(503):444-447.
74. MORRISON DS, GILCHRIST G, AHMED S: Potential of specialist drug services to deliver hepatitis B vaccination. Commun. Dis. Public Health (2002) 5(4):321-323.
75. WRIGHT NM, CAMPBELL TL, TOMPKINS CN: Comparison of conventional and accelerated hepatitis B immunization schedules for homeless drug users. Commun. Dis. Public Health (2002) 5(4):324-326.
76. http://www.cdc.gov/ncidod/diseases/hepatitis/ resource/dz_burden02.htm NATIONAL CENTER FOR INFECTIOUS DISEASES VIRAL HEPATITIS SURVEILLANCE: Disease burden from hepatitis A, B, C in the United States. Accessed 12 July 2006.
77. http://www.cdc.gov/idu CENTERS FOR DISEASE CONTROL AND PREVENTION: Viral hepatitis and injection drug users. Accessed 24 July 2006.